Sunday saw the running of the 2020 City to Surf virtual event.
While this year, we were unable to run as part of a large team as we have done in past years, CRBF was fortunate to have teams competing in many parts of Sydney.
We were truly humbled by the support, and whilst we are still yet to finalise the total figure for monies raised on the day, initial reports would suggest sarcoma research will be the big winner, with 100% of funds raised directed to the IL-23 sarcoma sub-study, at the Garvan Institute of Medical Research. https://www.trialsitenews.com/the-force-of-cooper-rice-brading-the-garvan-institute-research-in-australia-will-include-il23-in-sarcoma-clinical-trial/
Our heartfelt thanks to each of our outstanding participants who were prepared to compete, despite the miserable weather forecast.
Mark the 2021 event in your diary , and we will see you all again next year!
A project harnessing modified immune cells to target cancers will see Sydney leading innovative cancer therapies.
The University of Sydney and Children’s Medical Research Institute (CMRI) have announced the execution of an agreement with biopharmaceutical company, Biosceptre (BCIQ), to establish a new research program on CAR-T cell immunotherapy, at Westmead, Western Sydney.
To read more about this remarkable research, and Dr Patrick Schlegel, the German paediatric oncologist, and leader in CAR-T technology, who will be leading the Sydney research team, press the link below
A team of scientists led by Western Australian based scientist Dr. Emel Rothzerg – School of Biomedical Sciences at the University of The University of Western Australia, in Perth (Australia) and the Perron Institute for Neurological and Translational Science in Nedlands (Australia), reports an association between osteosarcoma and abnormal alternative splicing of the leptin receptor overlapping transcript (LEPROT).